Kaisary A V, Tyrrell C J, Peeling W B, Griffiths K
Department of Urology, Royal Free Hospital, London.
Br J Urol. 1991 May;67(5):502-8. doi: 10.1111/j.1464-410x.1991.tb15195.x.
Between November 1983 and February 1986, 358 patients with previously untreated metastatic prostatic carcinoma entered a multicentre, randomised trial in the United Kingdom and the Republic of Ireland, in which the LHRH analogue Zoladex (ICI Pharmaceuticals PLC), administered subcutaneously every 28 days, was compared with orchiectomy. Both treatments were equally effective in lowering serum testosterone concentrations to within the surgically castrate range and this was accompanied by equivalent subjective and objective response rates and times to treatment failure. At a median follow-up of 2 years there was no difference in overall survival, confirming that Zoladex is an effective medical alternative to orchiectomy in patients with metastatic disease.
1983年11月至1986年2月期间，358例先前未经治疗的转移性前列腺癌患者在英国和爱尔兰共和国参加了一项多中心随机试验，该试验将每28天皮下注射一次的促性腺激素释放激素（LHRH）类似物诺雷德（ICI制药公司）与睾丸切除术进行了比较。两种治疗方法在将血清睾酮浓度降低到手术去势范围内同样有效，并且伴有相当的主观和客观缓解率以及至治疗失败时间。在中位随访2年时，总生存率没有差异，证实诺雷德是转移性疾病患者睾丸切除术的一种有效的医学替代方法。
